Extension Study of RA101495 for Patients With PNH Who Have Completed a RA101495 Clinical Study
| Status: | Recruiting |
|---|---|
| Conditions: | Hematology, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/24/2018 |
| Start Date: | July 17, 2017 |
| End Date: | January 2020 |
| Contact: | Sponsor Ra Pharmaceuticals, Inc. |
| Email: | trials@rapharma.com |
| Phone: | +1 617 401 4060 |
A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study
The purpose of this study is to enable continued access to RA101495 for patients with
paroxysmal nocturnal hemoglobinuria (PNH) after they complete a RA101495 clinical study.
paroxysmal nocturnal hemoglobinuria (PNH) after they complete a RA101495 clinical study.
Inclusion Criteria:
- Completion of a qualifying Ra Pharmaceuticals sponsored RA101495 PNH study
- Evidence of ongoing clinical benefit in the opinion of the Investigator
Exclusion criteria:
- History of meningococcal disease
- Current systemic infection or suspicion of active bacterial infection
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials